Relay Therapeutics, Inc. Increase (Decrease) in Commodity Contract Assets and Liabilities
Relay Therapeutics, Inc. (RLAY) reported Increase (Decrease) in Commodity Contract Assets and Liabilities of -$4.91 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInCommodityContractAssetsAndLiabilities · last filed 2026-02-26
- Relay Therapeutics, Inc. increase (decrease) in commodity contract assets and liabilities for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in commodity contract assets and liabilities for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in commodity contract assets and liabilities for the quarter ending 2023-06-30 was -$4.95M, a 5783.91% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in commodity contract assets and liabilities for the quarter ending 2023-03-31 was $32.00K, a 77.14% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in commodity contract assets and liabilities for fiscal 2023 was -$4.91M, a 1406.65% decline from fiscal 2022.
- Relay Therapeutics, Inc. increase (decrease) in commodity contract assets and liabilities for fiscal 2022 was $376.00K.
- Relay Therapeutics, Inc. increase (decrease) in commodity contract assets and liabilities for fiscal 2021 was -$3.12M, a 140.72% decline from fiscal 2020.
- Relay Therapeutics, Inc. increase (decrease) in commodity contract assets and liabilities for fiscal 2020 was $7.65M.
| Period end | Increase (Decrease) in Commodity Contract Assets and Liabilities 3 month | Increase (Decrease) in Commodity Contract Assets and Liabilities 6 month | Increase (Decrease) in Commodity Contract Assets and Liabilities 9 month | Increase (Decrease) in Commodity Contract Assets and Liabilities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | -$4.95M derived: sum of 3 quarters · filed 2026-02-26 | -$4.91M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$4.95M derived: sum of 2 quarters · filed 2024-11-06 | -$4.91M 10-Q · filed 2024-11-06 | -$4.88M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$4.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$4.91M 10-Q · filed 2024-08-06 | -$4.88M derived: sum of 3 quarters · filed 2025-02-26 | -$4.76M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $32.00K 10-Q · filed 2024-05-02 | $69.00K derived: sum of 2 quarters · filed 2025-02-26 | $181.00K derived: sum of 3 quarters · filed 2025-02-26 | $268.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $149.00K derived: sum of 2 quarters · filed 2025-02-26 | $236.00K derived: sum of 3 quarters · filed 2025-02-26 | $376.00K 10-K · filed 2025-02-26 |
| 2022-09-30 | $112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $199.00K derived: sum of 2 quarters · filed 2023-11-02 | $339.00K 10-Q · filed 2023-11-02 | $625.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $87.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $227.00K 10-Q · filed 2023-08-08 | $513.00K derived: sum of 3 quarters · filed 2024-02-22 | $572.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $140.00K 10-Q · filed 2023-05-04 | $426.00K derived: sum of 2 quarters · filed 2024-02-22 | $485.00K derived: sum of 3 quarters · filed 2024-02-22 | -$3.93M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $286.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $345.00K derived: sum of 2 quarters · filed 2024-02-22 | -$4.07M derived: sum of 3 quarters · filed 2024-02-22 | -$3.12M 10-K · filed 2024-02-22 |
| 2021-09-30 | $59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$4.36M derived: sum of 2 quarters · filed 2022-11-03 | -$3.40M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$4.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$3.46M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $952.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $7.65M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |